- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.05. | Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders | 369 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of shareholders... ► Artikel lesen | |
| PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 24.04. | Psyence Group Inc (2): Psyence amends merger agreement with GoldCoast | 2 | Stockwatch | ||
| 24.04. | Psyence Group Inc. Announces Amendment to Amalgamation Agreement with GoldCoast Resource Corp. | 92 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / April 23, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that it has entered into an amendment dated April 13, 2026 (the "Amendment")... ► Artikel lesen | |
| 25.03. | Psyence Group Inc (2): Psyence target GoldCoast closes tranche 2 of financing | 1 | Stockwatch | ||
| 25.03. | Psyence Group Inc.: Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering | 793 | ACCESS Newswire | Combined aggregate with previous tranche of $8,603,883 TORONTO, ON / ACCESS Newswire / March 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that GoldCoast Resource Corp.... ► Artikel lesen | |
| 24.02. | Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp. | 549 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / February 24, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that it has entered into an amending agreement (the "Amending Agreement") dated... ► Artikel lesen | |
| 28.01. | Psyence Group Inc (2): Psyence RTO target receives reconnaissance licences | 1 | Stockwatch | ||
| 27.01. | Psyence Group Inc.: Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf | 1.197 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast")... ► Artikel lesen | |
| 25.11.25 | XFRA EKW0: AUSSETZUNG/SUSPENSION | 223 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPSYENCE GROUP INC.... ► Artikel lesen | |
| 24.11.25 | CSE Bulletin: Halted for Fundamental Change - Psyence Group Inc. (PSYG) | 373 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - Trading in the shares of Psyence Group Inc. (PSYG) will remain halted pending receipt and review of acceptable documentation regarding... ► Artikel lesen | |
| 24.11.25 | Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp. | 591 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 24, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has... ► Artikel lesen | |
| 17.10.25 | Psyence Group Inc. Announces RSU Grants | 600 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU")... ► Artikel lesen | |
| 22.08.25 | XFRA EKW0: WIEDERAUFNAHME/RESUMPTION | 532 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 22.08.25 | Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp. | 570 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the... ► Artikel lesen | |
| 07.07.25 | Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds | 582 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,280 | +22,38 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,950 | +6,90 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| TANGO THERAPEUTICS | 30,370 | +5,89 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 265,29 | +10,23 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| MBX BIOSCIENCES | 34,340 | -7,81 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| NURIX THERAPEUTICS | 17,150 | +12,09 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,020 | +5,23 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,440 | -1,35 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) | ||
| APOGEE THERAPEUTICS | 88,02 | +6,41 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| ALUMIS | 23,930 | +19,29 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| PARABILIS MEDICINES | 28,000 | -11,39 % | HBM Healthcare Investments AG: HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
11.06.2026 / 07:00... ► Artikel lesen | |
| ABSCI | 6,595 | +3,37 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,870 | -1,84 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,170 | +0,63 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen |
Das Unternehmen PSYENCE GROUP INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,064 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE GROUP INC finden Sie auf Wallstreet Online.